Psychiatry

A study of 7 million-plus US adults shows telehealth visits for mental health conditions increased more than 10-fold during the COVID-19 pandemic.

A large systematic review assessing more than 60 drugs for bipolar depression shows only a handful were statistically signifcantly better than placebo per depressive symptom outcomes.

A proof-of-concept trial shows a program that addresses sleep pressure, circadian rhythm and hyperarousal in adolescents and young adults receiving mental health care is promising.

New cohort analysis shows residents entering medicine in 2020 were actually less likely to report symptoms of PTSD than their earlier peers.

The pioneer in social anxiety disorder discusses how the investigative nasal spay may alter the trajectory of patients' conditions.

The pioneer in social anxiety disorder discusses his involvement in a promising, fast-acting nasal spray showing promising outcomes in late-stage trials.

Instances of urgent IBD hospitalization, surgery, death or lack of response to steroid therapy are linked to symptoms of depression and anxiety.

Vistagen reported significant improvement of physician- and patient-reported anxiety among trial participants who underwent an anxiety-inducing public speaking exercise.

Clayton, a primary investigator in the drug's pivotal trials, discusses what the historic FDA approval means for managing PPD in women.

The approval marks the first indication for a postpartum depression drug—one that which has been touted for its rapid-acting effect and sustained benefits.

The results found those with sexual minority status were significantly more likely to attend prenatal care visits (20%) when compared with heterosexual women.

While tele-CBT did not lead to significant changes in short-term weight outcomes, it was effective in improving disordered eating behaviors and reducing psychological distress.

"Depression causes a large public health burden, and alcohol-related behavior is a potentially modifiable risk factor," Dr. Gemma Hammerton writes.

The baseline data for the initial 1000 participants recruited into the TX-YDSRN show 79.6% were diagnosed with a primary depressive disorder.

Investigators discuss the potential of psychedelic drugs as a new approach to treating mental illnesses, highlighting their therapeutic benefits and the need for further research to understand their effects, safety, and accessibility.

During the early pandemic period, video telehealth use increased among all veteran groups but differences were observed among American Indian/Alaska Native veterans.

After restrictions, the number of youth more than 1 hour away from a clinic almost doubled to 50%, indicating that half of all youths face increased travel times to access essential gender-affirming care.

RiVive is the second nonprescription naloxone product approved by the FDA, signaling a proactive effort to increase accessibility and consumer availability of life-saving medication.

The study suggests 1 in every 18 patients would need an MRI scan to detect such significant abnormalities.

Results show 60% of the children with FASD experienced nightmares, while 44% exhibited frequent insomnia symptoms.

Structural discrimination, such as sexism and racism, can exacerbate mental health challenges, leading to higher suicidal thoughts and behavior rates among multiple marginalized individuals.

Because early detection of PPD is crucial and its prevalence is growing in the US, the condition poses significant risks to both maternal and neonatal health.

Data corresponding with DSM-IV symptoms were gathered around ages 18, 21, and 23 years and the primary outcome was depression at age 24.

Investigators noted both direct and indirect standardization are valid methods for comparing mortality rates. However, direct standardization is particularly useful when assessing disease burdens across multiple groups.

The findings underscore the importance of considering both the severity of BPD features and changes in depressive symptoms when assessing risk of suicide.